Hideki Terai

2.3k total citations
41 papers, 778 citations indexed

About

Hideki Terai is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Hideki Terai has authored 41 papers receiving a total of 778 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 21 papers in Molecular Biology and 16 papers in Oncology. Recurrent topics in Hideki Terai's work include Lung Cancer Treatments and Mutations (21 papers), Lung Cancer Research Studies (6 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). Hideki Terai is often cited by papers focused on Lung Cancer Treatments and Mutations (21 papers), Lung Cancer Research Studies (6 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). Hideki Terai collaborates with scholars based in Japan, United States and United Kingdom. Hideki Terai's co-authors include Kenzo Soejima, Shinnosuke Ikemura, Katsuhiko Naoki, Takashi Sato, Satoshi Yoda, Sohei Nakayama, Ryosuke Satomi, Tomoko Betsuyaku, Hiroyuki Yasuda and Junko Hamamoto and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Cancer Research.

In The Last Decade

Hideki Terai

36 papers receiving 772 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hideki Terai Japan 15 480 358 297 199 45 41 778
Andreas Varkaris United States 17 393 0.8× 327 0.9× 331 1.1× 253 1.3× 46 1.0× 46 836
Jens Enoksson Sweden 6 532 1.1× 246 0.7× 353 1.2× 176 0.9× 64 1.4× 8 763
Raul Ayala United States 9 483 1.0× 253 0.7× 356 1.2× 124 0.6× 69 1.5× 18 830
Inés López Spain 10 396 0.8× 198 0.6× 280 0.9× 258 1.3× 46 1.0× 18 664
Christine To Canada 9 391 0.8× 173 0.5× 323 1.1× 196 1.0× 43 1.0× 11 708
R. Molife United Kingdom 11 300 0.6× 277 0.8× 291 1.0× 162 0.8× 34 0.8× 24 694
Katherine R. Singleton United States 11 497 1.0× 190 0.5× 209 0.7× 135 0.7× 50 1.1× 16 652
David Molkentine United States 16 371 0.8× 186 0.5× 357 1.2× 125 0.6× 37 0.8× 30 708
François Ringeisen France 14 517 1.1× 305 0.9× 373 1.3× 175 0.9× 57 1.3× 33 899
Hideaki Mitsui Japan 18 393 0.8× 290 0.8× 320 1.1× 206 1.0× 38 0.8× 47 863

Countries citing papers authored by Hideki Terai

Since Specialization
Citations

This map shows the geographic impact of Hideki Terai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hideki Terai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hideki Terai more than expected).

Fields of papers citing papers by Hideki Terai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hideki Terai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hideki Terai. The network helps show where Hideki Terai may publish in the future.

Co-authorship network of co-authors of Hideki Terai

This figure shows the co-authorship network connecting the top 25 collaborators of Hideki Terai. A scholar is included among the top collaborators of Hideki Terai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hideki Terai. Hideki Terai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chubachi, Shotaro, Jun Miyata, Junko Hamamoto, et al.. (2025). Celecoxib prevents malignant progression of smoking-induced lung tumors via suppression of the COX-2/PGE2 signaling pathway in mice. Frontiers in Immunology. 16. 1557790–1557790.
2.
Fukunaga, Noritaka, Hideki Terai, Yutaka Kurebayashi, et al.. (2025). Acquisition of FGFR1 and NSD3 Amplifications During the Transformation of EGFR-Mutated Lung Adenocarcinoma into Squamous Cell Carcinoma: A Case Report. JTO Clinical and Research Reports. 6(9). 100862–100862.
3.
Nakayama, Shingo, Shotaro Chubachi, Takashi Shimada, et al.. (2025). Roflumilast reduces the number of lung adenocarcinomas, inflammation, and emphysema in a smoking-induced mouse model. BMC Pulmonary Medicine. 25(1). 262–262.
4.
Okada, Masahiko, Kohei Horiuchi, Koichi Sayama, et al.. (2024). Real-World Efficacy and Safety of Atezolizumab for Advanced Non-Small Cell Lung Cancer in Japan: A Retrospective Multicenter Analysis. Journal of Clinical Medicine. 13(24). 7815–7815. 1 indexed citations
5.
Yagi, Kazuma, Takanori Asakura, Hideki Terai, et al.. (2023). Clinical features of Japanese patients with gastrointestinal long‐COVID symptoms. JGH Open. 7(12). 998–1002. 2 indexed citations
6.
Horiuchi, Kohei, Shinnosuke Ikemura, Takashi Sato, et al.. (2023). Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective Analysis. The Oncologist. 29(1). e108–e117. 12 indexed citations
7.
Toyonaga, Takahiko, Taku Kobayashi, Aito Ueno, et al.. (2021). Increased DNA-incorporated thiopurine metabolite as a possible mechanism for leukocytopenia through cell apoptosis in inflammatory bowel disease patients with NUDT15 mutation. Journal of Gastroenterology. 56(11). 999–1007. 10 indexed citations
8.
Tani, Tetsuo, Ichiro Nakachi, Shinnosuke Ikemura, et al.. (2021). Clinical Characteristics and Therapeutic Outcomes of Metastatic Peritoneal Carcinomatosis in Non-Small-Cell Lung Cancer. Cancer Management and Research. Volume 13. 7497–7503. 6 indexed citations
9.
Lee, Ho, Hideki Terai, Makoto Ishii, et al.. (2021). Finding of the factors affecting the severity of COVID-19 based on mathematical models. Scientific Reports. 11(1). 24224–24224. 6 indexed citations
10.
Terai, Hideki, Junko Hamamoto, Katsura Emoto, et al.. (2020). SHOC2 Is a Critical Modulator of Sensitivity to EGFR–TKIs in Non–Small Cell Lung Cancer Cells. Molecular Cancer Research. 19(2). 317–328. 13 indexed citations
11.
Manabe, Tadashi, Hiroyuki Yasuda, Hideki Terai, et al.. (2020). IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer. Molecular Cancer Research. 18(4). 549–559. 39 indexed citations
12.
Terai, Hideki, et al.. (2020). Analysis of clinical outcomes in elderly patients with impaired swallowing function. PLoS ONE. 15(9). e0239440–e0239440. 5 indexed citations
13.
Yasuda, Hiroyuki, Keigo Kobayashi, Tetsuo Tani, et al.. (2019). Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab. Molecular Cancer Therapeutics. 18(9). 1593–1601. 3 indexed citations
14.
Xu, Chunxiao, Kevin A. Buczkowski, Hajime Asahina, et al.. (2015). NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy. Molecular Cancer Therapeutics. 14(10). 2382–2389. 24 indexed citations
15.
Ikemura, Shinnosuke, Katsuhiko Naoki, Hiroyuki Yasuda, et al.. (2015). A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer. Japanese Journal of Clinical Oncology. 45(4). 356–361. 6 indexed citations
16.
Terai, Hideki, Kenzo Soejima, Hiroyuki Yasuda, et al.. (2014). Long-term exposure to gefitinib induces acquired resistance through DNA methylation changes in the EGFR-mutant PC9 lung cancer cell line. International Journal of Oncology. 46(1). 430–436. 12 indexed citations
17.
Terai, Hideki, Kenzo Soejima, Hiroyuki Yasuda, et al.. (2013). Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC. Molecular Cancer Research. 11(7). 759–767. 174 indexed citations
18.
Hamamoto, Junko, Kenzo Soejima, Satoshi Yoda, et al.. (2013). Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma. Molecular Medicine Reports. 8(2). 456–462. 54 indexed citations
19.
Naoki, Katsuhiko, Kenzo Soejima, Hiroaki Okamoto, et al.. (2011). The PCR-invader method (structure-specific 5′ nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing. International Journal of Clinical Oncology. 16(4). 335–344. 39 indexed citations
20.
Yasuda, Hiroyuki, Kenzo Soejima, Sohei Nakayama, et al.. (2010). Bronchoscopic Microsampling is a Useful Complementary Diagnostic Tool for Detecting Lung Cancer. Lung Cancer. 72(1). 32–38. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andreas Varkaris Breakdown of academic impact, for papers by Jens Enoksson Breakdown of academic impact, for papers by Raul Ayala Breakdown of academic impact, for papers by Inés López Breakdown of academic impact, for papers by Christine To Breakdown of academic impact, for papers by R. Molife Breakdown of academic impact, for papers by Katherine R. Singleton Breakdown of academic impact, for papers by David Molkentine Breakdown of academic impact, for papers by François Ringeisen Breakdown of academic impact, for papers by Hideaki Mitsui
Rankless by CCL
2026